EDAP TMS Showcases Focal One HIFU at Oppenheimer Conference

The latest update is out from EDAP TMS ( (EDAP) ).

On March 18, 2026, EDAP TMS will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, highlighting its Focal One robotic HIFU technology as a best-in-class, image-guided focal therapy for prostate cancer within a roughly 1.5 million-case-per-year global market. The company underscores strong clinical evidence showing comparable or superior oncologic outcomes versus radical prostatectomy and radiation, improved functional results in continence and sexual function, rapidly growing HIFU adoption, and a favorable U.S. reimbursement environment that together support accelerating hospital uptake and strengthen EDAP’s positioning in the prostate cancer treatment landscape.

The most recent analyst rating on (EDAP) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.

Spark’s Take on EDAP Stock

According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow), despite strong technical momentum and encouraging earnings-call fundamentals around accelerating HIFU growth and maintained guidance. Valuation is neutral-to-weak due to negative earnings and no dividend support.

To see Spark’s full report on EDAP stock, click here.

More about EDAP TMS

EDAP TMS S.A. operates in the healthcare MedTech sector as a global leader in therapeutic ultrasound, focusing on robotic high-intensity focused ultrasound (HIFU) systems for the treatment of prostate cancer and benign diseases. Its flagship Focal One platform targets a large and growing urology market, particularly the underserved segment of prostate cancer patients seeking organ-preserving, focal therapies that balance cancer control with quality-of-life outcomes.

Average Trading Volume: 69,165

Technical Sentiment Signal: Hold

Current Market Cap: $151.8M

For an in-depth examination of EDAP stock, go to TipRanks’ Overview page.